Captrust Financial Advisors Grows Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Captrust Financial Advisors increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 648.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,730 shares of the medical research company's stock after purchasing an additional 4,964 shares during the period. Captrust Financial Advisors' holdings in Bio-Rad Laboratories were worth $1,882,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in BIO. Metis Global Partners LLC boosted its stake in Bio-Rad Laboratories by 4.4% in the 4th quarter. Metis Global Partners LLC now owns 712 shares of the medical research company's stock worth $234,000 after purchasing an additional 30 shares during the period. Signaturefd LLC boosted its position in shares of Bio-Rad Laboratories by 13.2% during the 4th quarter. Signaturefd LLC now owns 265 shares of the medical research company's stock valued at $87,000 after acquiring an additional 31 shares in the last quarter. UMB Bank n.a. lifted its holdings in Bio-Rad Laboratories by 41.6% during the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company's stock valued at $36,000 after purchasing an additional 32 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Bio-Rad Laboratories by 0.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company's stock worth $1,488,000 after buying an additional 32 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Bio-Rad Laboratories by 3.9% during the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company's stock worth $296,000 after buying an additional 34 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on BIO. Royal Bank of Canada dropped their price objective on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Citigroup dropped their price target on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company lowered their price objective on shares of Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. UBS Group lowered their price objective on shares of Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Finally, StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $327.40.

Bio-Rad Laboratories Price Performance

NYSE BIO traded up $5.26 during trading hours on Friday, reaching $248.45. The company's stock had a trading volume of 254,950 shares, compared to its average volume of 321,515. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. Bio-Rad Laboratories, Inc. has a 1 year low of $215.38 and a 1 year high of $387.99. The firm's 50-day moving average price is $243.46 and its 200-day moving average price is $298.10. The company has a market capitalization of $6.96 billion, a price-to-earnings ratio of -3.82 and a beta of 1.00.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The business had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same quarter in the prior year, the company earned $2.30 EPS. The business's revenue was down 4.2% compared to the same quarter last year. On average, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.